Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Dow
Johnson and Johnson
Medtronic
Boehringer Ingelheim

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020379

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 020379 describes CAVERJECT, which is a drug marketed by Pfizer and Pharmacia And Upjohn and is included in three NDAs. It is available from one supplier. Additional details are available on the CAVERJECT profile page.

The generic ingredient in CAVERJECT is alprostadil. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the alprostadil profile page.
Summary for 020379
Tradename:CAVERJECT
Applicant:Pharmacia And Upjohn
Ingredient:alprostadil
Patents:0
Pharmacology for NDA: 020379
Medical Subject Heading (MeSH) Categories for 020379
Suppliers and Packaging for NDA: 020379
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CAVERJECT alprostadil INJECTABLE;INJECTION 020379 NDA Pharmacia and Upjohn Company LLC 0009-3701 0009-3701-05 6 VIAL, SINGLE-DOSE in 1 PACKAGE (0009-3701-05) > 1 mL in 1 VIAL, SINGLE-DOSE (0009-3701-08)
CAVERJECT alprostadil INJECTABLE;INJECTION 020379 NDA Pharmacia and Upjohn Company LLC 0009-7686 0009-7686-04 6 VIAL, SINGLE-DOSE in 1 PACKAGE (0009-7686-04) > 1 mL in 1 VIAL, SINGLE-DOSE (0009-7686-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength0.01MG/VIAL
Approval Date:Jul 6, 1995TE:APRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength0.02MG/VIAL
Approval Date:Jul 6, 1995TE:APRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength0.005MG/VIAL
Approval Date:Jun 27, 1996TE:RLD:Yes

Expired US Patents for NDA 020379

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn CAVERJECT alprostadil INJECTABLE;INJECTION 020379-003 Jun 27, 1996   Start Trial   Start Trial
Pharmacia And Upjohn CAVERJECT alprostadil INJECTABLE;INJECTION 020379-004 May 19, 1997   Start Trial   Start Trial
Pharmacia And Upjohn CAVERJECT alprostadil INJECTABLE;INJECTION 020379-002 Jul 6, 1995   Start Trial   Start Trial
Pharmacia And Upjohn CAVERJECT alprostadil INJECTABLE;INJECTION 020379-002 Jul 6, 1995   Start Trial   Start Trial
Pharmacia And Upjohn CAVERJECT alprostadil INJECTABLE;INJECTION 020379-001 Jul 6, 1995   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Johnson and Johnson
Colorcon
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.